Brokerages Set Sucampo Pharmaceuticals, Inc. (SCMP) Target Price at $16.71

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $16.71.

A number of equities analysts have recently commented on the stock. Roth Capital set a $27.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 11th. Jefferies Group LLC reiterated a “hold” rating and set a $14.00 price target (down previously from $16.00) on shares of Sucampo Pharmaceuticals in a report on Saturday, March 11th. Maxim Group set a $19.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 11th. ValuEngine lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Mizuho reiterated a “buy” rating and set a $16.00 price target on shares of Sucampo Pharmaceuticals in a report on Monday, March 6th.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 1.04% on Friday, reaching $9.75. 304,139 shares of the company traded hands. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $17.55. The company has a market capitalization of $453.02 million, a PE ratio of 16.25 and a beta of 1.40. The stock has a 50-day moving average of $10.24 and a 200 day moving average of $11.60.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by $0.05. The company had revenue of $56.30 million during the quarter, compared to analyst estimates of $54.15 million. Sucampo Pharmaceuticals had a net margin of 11.36% and a return on equity of 43.27%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.21 EPS. On average, equities analysts forecast that Sucampo Pharmaceuticals will post $1.04 EPS for the current year.

WARNING: “Brokerages Set Sucampo Pharmaceuticals, Inc. (SCMP) Target Price at $16.71” was first posted by BBNS and is owned by of BBNS. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://baseballnewssource.com/markets/sucampo-pharmaceuticals-inc-scmp-receives-16-71-average-price-target-from-brokerages-updated/985254.html.

A number of institutional investors have recently made changes to their positions in the company. Louisiana State Employees Retirement System purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $111,000. Envestnet Asset Management Inc. purchased a new position in shares of Sucampo Pharmaceuticals during the fourth quarter worth $115,000. Karp Capital Management Corp purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $119,000. Capstone Asset Management Co. purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $133,000. Finally, New York State Teachers Retirement System purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $137,000. 57.00% of the stock is owned by institutional investors and hedge funds.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third
Injury to Gleyber Torres Adds to Questions About Yankees
Injury to Gleyber Torres Adds to Questions About Yankees
Game Winning Home Run Completes Nolan Arenado Cycle
Game Winning Home Run Completes Nolan Arenado Cycle
New York Yankees and Masahiro Tanaka Hit Hard Again
New York Yankees and Masahiro Tanaka Hit Hard Again
Victor Martinez Diagnosed with Irregular Heartbeat
Victor Martinez Diagnosed with Irregular Heartbeat


Leave a Reply

 
© 2006-2017 BBNS.